查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080388

抗生素市場：2026-2032年全球市場預測（依藥物類別、類型、抗菌頻譜、給藥途徑、應用及通路分類）

Antibiotics Market by Drug Class, Type, Spectrum, Route Of Administration, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗生素市場規模將成長至 793.8 億美元，複合年成長率為 7.14%。

主要市場統計數據
基準年 2025 489.7億美元
預計年份：2026年 522.5億美元
預測年份：2032年 793.8億美元
複合年成長率 (%) 7.14%

抗生素市場概覽及策略重要性

抗生素市場仍然是現代醫學的重要支柱，為醫院、門診、外科手術、腫瘤科、器官移植科、產科和重症監護室的細菌感染疾病治療提供支援。持續的感染疾病負擔、人口老化、外科手術量的增加以及對社區獲得性感染和醫療相關感染有效抗菌療法的持續需求，共同塑造了抗生素市場的需求。

抗生素市場的變革性變化

抗生素的使用格局正從以劑量為中心的模式轉向以實證醫學為基礎、並考慮抗生素抗藥性的治療模式。醫療衛生系統正在加強抗菌藥物管理項目，並擴大培養檢測和快速診斷方法的使用。採購工作也正按照基​​本藥物框架進行，例如世界衛生組織的「可及性抗生素」（AWaRe）分類。該框架旨在鼓勵更廣泛地使用被列為「可及」的抗生素，同時保護被列為「觀察」和「儲備」的藥物。

人工智慧在抗菌藥物領域的累積影響

人工智慧（AI）正開始影響抗生素的發現、最佳化、監測和臨床決策。經過同行評審的研究表明，人工智慧能夠識別出新型抗菌候選藥物，例如哈利辛和阿巴辛，這表明機器學習可以以傳統實驗室工作流程無法企及的速度篩檢化學空間。

抗生素市場關鍵區域洞察

亞太地區人口眾多，感染疾病負擔沉重，醫療保健覆蓋率不斷擴大，且大規模的學名藥生產能力，因此成為抗生素的主要需求中心。中國、印度、日本、韓國和澳洲是該價值鏈的重要組成部分。北美地區則受益於其先進的醫院系統、感染疾病監測、強制性抗生素使用以及針對抗藥性革蘭氏陰性病菌感染的新藥的廣泛應用。美國在監管流程、醫院抗生素使用標準和商業化模式方面持續發揮重要作用。

全球抗生素市場關鍵群分析

東協的抗生素市場格局正在快速變化，醫療保健使用量的增加、感染疾病負擔的加重以及私人醫療保健的擴張都推動了抗生素的需求。同時，各國政府正在加強抗菌藥物抗藥性（AMR）計畫和合理用藥教育。海灣合作理事會（GCC）正投資於先進醫院、感染預防、檢查室現代化和採購系統，為支持合理配製的高品質抗菌藥物和診斷試劑創造了市場機會。

主要國家抗菌藥物市場的關鍵趨勢

在美國，需求主要集中在嚴重感染疾病、疾管中心主導的抗藥性監測以及醫院的合理用藥要求上，而門診患者的需求則側重於呼吸道、泌尿道和皮膚感染疾病。加拿大強調合理用藥和堅持使用處方，而墨西哥和巴西則在滿足廣泛用藥需求的同時，日益成長的監管壓力也促使人們關注處方管理、抗生素使用監測以及醫院感染預防等方面的問題。

抗生素產業領導者使用的實用建議

產業領導者應優先開發針對世界衛生組織和國家重點病原體（尤其是抗藥性革蘭氏陰性菌）的抗生素產品組合，同時透過臨床證據、病原體特異性、安全性以及符合合理使用要求等因素來區分產品。各組織需要投資生命週期管理、合併用藥策略、兒童製劑以及基本抗生素的穩定供應，以提高抗生素的可及性和抗風險能力。

抗生素市場洞察調查方法

本執行摘要採用以二手資料研究主導的調查方法編寫，整合了檢驗的公共衛生、監管、臨床和行業資訊來源。主要參考資料包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、歐洲疾病管制與預防中心 (ECDC) 的數據和指南、國家抗菌素抗藥性 (AMR) 應對計畫、同行評審文獻以及公開的監管資訊。

結論：抗生素市場的未來發展方向

抗生素市場正處於一個關鍵的十字路口，臨床需求、抗生素抗藥性、政策改革和技術創新在此交匯融合。儘管抗生素對醫療保健系統仍然至關重要，但未來的市場成功將取決於它們是否能透過合理使用（抗生素管理）和實證配方來維持其效用，同時提供有效的治療。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：抗生素市場：依藥物類別分類

  • BETA-內醯胺
    • 青黴素
      • 天然青黴素
      • 氨基青黴素
      • 抗青黴素青黴素
      • 抗假單胞菌青黴素
    • 頭孢菌素
      • 第一代
      • 第二代
      • 第三代
      • 第四代
      • 第五代
    • 碳青黴烯類
    • 單環胺基類抗生素
  • 大環內酯類
  • Fluoroquinolones
  • 四環黴素
  • Aminoglycosides
  • 醣肽和醣肽
  • 磺胺類藥物藥物和甲氧芐啶
  • Oxazolidinone系列
  • 硝基咪唑

第8章：抗生素市場：依類型分類

  • 自然的
  • 合成

第9章：抗生素市場：依抗菌頻譜

  • 頻譜
  • 窄頻譜

第10章：抗生素市場：依給藥途徑分類

  • 口服
  • 腸外
    • 靜脈
    • 肌肉內部
  • 外用
    • 皮膚科
    • 眼科
  • 吸入

第11章 抗生素市場：依應用領域分類

  • 人類
  • 動物

第12章：抗生素市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章：抗生素市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：抗生素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 抗生素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • AbbVie Inc
  • Astellas Pharma Inc
  • Astra Zeneca plc
  • Aurobindo Pharma Ltd
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Ltd
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • Glaxo Smith Kline plc
  • Johnson & Johnson Services Inc
  • Lupin Limited
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
Product Code: MRR-434CCDA0512F

The Antibiotics Market is projected to grow by USD 79.38 billion at a CAGR of 7.14% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 48.97 billion
Estimated Year [2026] USD 52.25 billion
Forecast Year [2032] USD 79.38 billion
CAGR (%) 7.14%

Antibiotics Market Overview and Strategic Importance

The antibiotics market remains a critical pillar of modern medicine, supporting the treatment of bacterial infections across hospitals, outpatient care, surgery, oncology, transplantation, maternal health, and intensive care. Demand is shaped by the persistent infectious disease burden, aging populations, increased surgical volumes, and the continued need for effective antibacterial therapy in both community-acquired and healthcare-associated infections.

At the same time, antimicrobial resistance is redefining industry priorities. The World Health Organization identifies antimicrobial resistance as one of the top global public health threats, and the 2019 global burden analysis estimated 1.27 million deaths directly attributable to bacterial AMR and 4.95 million deaths associated with it. This creates a dual market reality: antibiotics remain indispensable, but sustainable progress depends on innovation, stewardship, diagnostics, resilient supply chains, and policy-backed incentives that preserve clinical effectiveness.

Transformative Shifts in the Antibiotics Landscape

The antibiotics landscape is shifting from volume-led prescribing toward evidence-based, resistance-aware treatment models. Health systems are strengthening antimicrobial stewardship programs, increasing the use of culture-based testing and rapid diagnostics, and aligning procurement with essential medicines frameworks such as the WHO AWaRe classification, which encourages broader use of Access antibiotics while protecting Watch and Reserve agents.

Commercial models are also changing. Traditional antibiotic revenues are constrained by short treatment durations, generic competition, and stewardship-driven conservation, while development costs remain high. As a result, industry leaders are prioritizing differentiated mechanisms of action, narrow-spectrum agents, beta-lactamase inhibitor combinations, pathogen-specific therapies, and subscription-style reimbursement models that reward availability and clinical value rather than sales volume.

Cumulative Impact of Artificial Intelligence on Antibiotics

Artificial intelligence is beginning to influence antibiotic discovery, optimization, surveillance, and clinical decision support. Peer-reviewed studies have demonstrated AI-assisted identification of novel antibacterial candidates such as halicin and abaucin, illustrating how machine learning can screen chemical space at speeds not feasible through conventional laboratory workflows alone.

The cumulative impact of AI is most valuable when integrated with high-quality microbiology data, electronic health records, genomics, and stewardship protocols. AI can support earlier resistance detection, predict treatment failure risk, optimize empiric therapy, and strengthen pharmacovigilance. However, successful deployment requires validated datasets, clinical oversight, transparent algorithms, and regulatory alignment to ensure that automation improves antibiotic use without accelerating inappropriate prescribing.

Key Regional Insights for the Antibiotics Market

Asia-Pacific is a major demand center for antibiotics due to large populations, high infectious disease burden, expanding healthcare access, and significant generic manufacturing capacity, with China, India, Japan, South Korea, and Australia shaping different parts of the value chain. North America is driven by advanced hospital systems, infectious disease surveillance, stewardship mandates, and adoption of novel agents for resistant Gram-negative infections, while the United States remains influential in regulatory pathways, hospital antibiotic use standards, and commercialization models.

Latin America is marked by broad antibiotic access needs, uneven stewardship implementation, and rising investment in hospital infection control, with Brazil and Mexico serving as important regional markets. Europe is characterized by mature reimbursement systems, coordinated AMR policy, and stronger restrictions on inappropriate antibiotic use, with the European Union emphasizing surveillance, One Health action, and supply security. The Middle East is expanding specialist care, hospital infrastructure, and centralized procurement, particularly across GCC countries, while Africa faces the dual challenge of improving access to essential antibiotics and reducing misuse, substandard medicines, and treatment gaps.

Key Group Insights Across Global Antibiotics Markets

ASEAN represents a fast-evolving antibiotics environment where rising healthcare utilization, infectious disease burden, and expanding private care are increasing demand, while governments intensify AMR action plans and stewardship education. GCC countries are investing in advanced hospitals, infection prevention, laboratory modernization, and procurement systems, creating opportunities for high-quality antibacterial products and diagnostics that support responsible prescribing.

The European Union remains a global reference point for coordinated antimicrobial resistance surveillance, regulatory oversight, and One Health policy. BRICS countries combine large patient populations, manufacturing strength, and growing research and development ambitions, making them central to both access and innovation discussions. G7 markets drive global standards in antibiotic stewardship, reimbursement reform, and advanced clinical research, while NATO countries increasingly view antimicrobial resistance and medicine supply resilience as health security priorities linked to preparedness, military medicine, and defense readiness.

Key Country Insights in the Antibiotics Market

The United States combines high-value innovation, CDC-led resistance monitoring, and hospital stewardship requirements, with demand concentrated in severe infections, resistant pathogens, and outpatient respiratory, urinary, and skin infections. Canada emphasizes stewardship and formulary discipline, while Mexico and Brazil balance broad access needs with growing regulatory attention to prescription control, antimicrobial use monitoring, and hospital infection prevention.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature antibiotic markets shaped by national AMR strategies, reimbursement scrutiny, infection prevention standards, and demand for novel agents targeting resistant bacteria. Russia remains an important market with domestic production considerations and significant infectious disease treatment needs. In Asia-Pacific, China and India are central due to population scale, generics manufacturing, and policy efforts to improve antibiotic governance; Japan, Australia, and South Korea are advanced markets with strong stewardship, high clinical standards, robust diagnostics adoption, and interest in innovative therapies for resistant infections.

Actionable Recommendations for Antibiotics Industry Leaders

Industry leaders should prioritize antibiotic portfolios that address WHO and national priority pathogens, especially resistant Gram-negative bacteria, while differentiating products through clinical evidence, pathogen specificity, safety, and compatibility with stewardship requirements. Organizations should invest in lifecycle management, combination strategies, pediatric formulations, and reliable supply of essential antibiotics to strengthen both access and resilience.

Vendors should also align commercial strategies with diagnostics, surveillance data, and value-based reimbursement. Partnerships with hospitals, public health agencies, biotechnology innovators, and diagnostic developers can accelerate adoption while supporting responsible use. Preparing for subscription-style payment models, AMR pull incentives, and procurement criteria tied to supply continuity will be essential for long-term competitiveness.

Research Methodology for Antibiotics Market Insights

This executive summary is developed using a secondary research-led methodology that synthesizes verified public health, regulatory, clinical, and industry sources. Core reference points include data and guidance from the World Health Organization, Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, national AMR action plans, peer-reviewed literature, and publicly available regulatory information.

The analysis emphasizes evidence-backed market drivers, resistance trends, regional healthcare dynamics, stewardship policies, and technology adoption patterns. Insights are validated through triangulation across epidemiology, prescribing behavior, innovation pipeline trends, healthcare infrastructure, and policy developments to provide a balanced view of the antibiotics market without relying on unsupported estimates, market sizing, or forecasting.

Conclusion: Future Direction for the Antibiotics Market

The antibiotics market is entering a decisive phase in which clinical necessity, antimicrobial resistance, policy reform, and technological innovation are converging. Antibiotics will remain essential to healthcare systems, but future market success will depend on delivering effective therapies while preserving their utility through stewardship and evidence-based prescribing.

Organizations that combine scientific differentiation, responsible commercialization, AI-enabled discovery, rapid diagnostics, and resilient manufacturing will be best positioned to lead. As AMR continues to shape global health priorities, the antibiotics industry must balance access, innovation, and conservation to sustain long-term value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Antibiotics Market, by Drug Class

  • 7.1. Beta-Lactams
    • 7.1.1. Penicillins
      • 7.1.1.1. Natural Penicillins
      • 7.1.1.2. Aminopenicillins
      • 7.1.1.3. Penicillinase-Resistant Penicillins
      • 7.1.1.4. Antipseudomonal Penicillins
    • 7.1.2. Cephalosporins
      • 7.1.2.1. First Generation
      • 7.1.2.2. Second Generation
      • 7.1.2.3. Third Generation
      • 7.1.2.4. Fourth Generation
      • 7.1.2.5. Fifth Generation
    • 7.1.3. Carbapenems
    • 7.1.4. Monobactams
  • 7.2. Macrolides
  • 7.3. Fluoroquinolones
  • 7.4. Tetracyclines
  • 7.5. Aminoglycosides
  • 7.6. Glycopeptides And Lipoglycopeptides
  • 7.7. Sulfonamides And Trimethoprim
  • 7.8. Oxazolidinones
  • 7.9. Nitroimidazoles

8. Antibiotics Market, by Type

  • 8.1. Natural
  • 8.2. Synthetic

9. Antibiotics Market, by Spectrum

  • 9.1. Broad Spectrum
  • 9.2. Narrow Spectrum

10. Antibiotics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intravenous
    • 10.2.2. Intramuscular
  • 10.3. Topical
    • 10.3.1. Dermatological
    • 10.3.2. Ophthalmic
  • 10.4. Inhalation

11. Antibiotics Market, by Application

  • 11.1. Human
  • 11.2. Veterinary

12. Antibiotics Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antibiotics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Antibiotics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antibiotics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. AbbVie Inc
  • 17.3. Astellas Pharma Inc
  • 17.4. Astra Zeneca plc
  • 17.5. Aurobindo Pharma Ltd
  • 17.6. Bayer AG
  • 17.7. Bristol Myers Squibb Company
  • 17.8. Cipla Ltd
  • 17.9. Dr Reddy's Laboratories Ltd
  • 17.10. Eli Lilly and Company
  • 17.11. Glaxo Smith Kline plc
  • 17.12. Johnson & Johnson Services Inc
  • 17.13. Lupin Limited
  • 17.14. Merck & Co Inc
  • 17.15. Novartis AG
  • 17.16. Pfizer Inc
  • 17.17. Sanofi S A
  • 17.18. Sun Pharmaceutical Industries Ltd
  • 17.19. Teva Pharmaceutical Industries Ltd
  • 17.20. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBIOTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ANTIBIOTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ANTIBIOTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ANTIBIOTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIBIOTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ANTIBIOTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BETA-LACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BETA-LACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BETA-LACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NATURAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AMINOPENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AMINOPENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AMINOPENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PENICILLINASE-RESISTANT PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSEUDOMONAL PENICILLINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIRST GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIRST GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIRST GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SECOND GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SECOND GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SECOND GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THIRD GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THIRD GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOURTH GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FOURTH GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOURTH GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIFTH GENERATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIFTH GENERATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIFTH GENERATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CARBAPENEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CARBAPENEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CARBAPENEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MONOBACTAMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MONOBACTAMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MONOBACTAMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MACROLIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MACROLIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MACROLIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TETRACYCLINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TETRACYCLINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TETRACYCLINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AMINOGLYCOSIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SULFONAMIDES AND TRIMETHOPRIM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OXAZOLIDINONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OXAZOLIDINONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OXAZOLIDINONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NITROIMIDAZOLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NATURAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NATURAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NATURAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL SYNTHETIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL SYNTHETIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL SYNTHETIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BROAD SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BROAD SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BROAD SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NARROW SPECTRUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NARROW SPECTRUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NARROW SPECTRUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DERMATOLOGICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DERMATOLOGICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DERMATOLOGICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPHTHALMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPHTHALMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OPHTHALMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. GCC ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. GCC ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 216. GCC ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. GCC ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 218. GCC ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. GCC ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 220. GCC ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 221. GCC ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. GCC ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. G7 ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. G7 ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. G7 ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 250. G7 ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 251. G7 ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. G7 ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 254. G7 ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. G7 ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 256. G7 ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 257. G7 ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. G7 ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. NATO ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. NATO ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 261. NATO ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 262. NATO ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. NATO ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 266. NATO ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. NATO ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 268. NATO ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 269. NATO ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. NATO ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 286. CANADA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 287. CANADA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 288. CANADA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 289. CANADA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CANADA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 296. MEXICO ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. MEXICO ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 298. MEXICO ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 299. MEXICO ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 300. MEXICO ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 301. MEXICO ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. MEXICO ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 303. MEXICO ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 308. BRAZIL ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 318. BRAZIL ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. BRAZIL ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 321. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 322. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 323. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 324. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 325. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 327. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED KINGDOM ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 332. GERMANY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 333. GERMANY ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 334. GERMANY ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 335. GERMANY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 336. GERMANY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 337. GERMANY ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. GERMANY ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 339. GERMANY ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 340. GERMANY ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 341. GERMANY ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 342. GERMANY ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 343. GERMANY ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 344. FRANCE ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 345. FRANCE ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 346. FRANCE ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 347. FRANCE ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 348. FRANCE ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 349. FRANCE ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. FRANCE ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 351. FRANCE ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 352. FRANCE ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 353. FRANCE ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 354. FRANCE ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 355. FRANCE ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 356. RUSSIA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 357. RUSSIA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 358. RUSSIA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 359. RUSSIA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 360. RUSSIA ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 361. RUSSIA ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 362. RUSSIA ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 363. RUSSIA ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 364. RUSSIA ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 365. RUSSIA ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 366. RUSSIA ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 367. RUSSIA ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 368. ITALY ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 369. ITALY ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 370. ITALY ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 371. ITALY ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 372. ITALY ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 373. ITALY ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 374. ITALY ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 375. ITALY ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 376. ITALY ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 377. ITALY ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 378. ITALY ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 379. ITALY ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 380. SPAIN ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 381. SPAIN ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 382. SPAIN ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 383. SPAIN ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)
  • TABLE 384. SPAIN ANTIBIOTICS MARKET SIZE, BY CEPHALOSPORINS, 2018-2032 (USD MILLION)
  • TABLE 385. SPAIN ANTIBIOTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 386. SPAIN ANTIBIOTICS MARKET SIZE, BY SPECTRUM, 2018-2032 (USD MILLION)
  • TABLE 387. SPAIN ANTIBIOTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 388. SPAIN ANTIBIOTICS MARKET SIZE, BY PARENTERAL, 2018-2032 (USD MILLION)
  • TABLE 389. SPAIN ANTIBIOTICS MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 390. SPAIN ANTIBIOTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 391. SPAIN ANTIBIOTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 392. CHINA ANTIBIOTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 393. CHINA ANTIBIOTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 394. CHINA ANTIBIOTICS MARKET SIZE, BY BETA-LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 395. CHINA ANTIBIOTICS MARKET SIZE, BY PENICILLINS, 2018-2032 (USD MILLION)

TABLE 396.